Description
Trametinib Tablet is a kinase inhibitor used as a single agent to treat BRAF-inhibitor treatment-naïve patients with unresectable or metastatic melanoma with mutations BRAF V600E/V600K. This therapeutic drug is also used, in combination with medicine dabrafenib, for:
-
- The treatment of patients with unresectable or metastatic melanoma with mutations BRAF V600E or V600K.
- The adjuvant treatment of patients with melanoma with mutations BRAF V600E or V600K, and involvement of lymph node(s), after complete resection.
- The treatment of patients with metastatic non-small cell lung cancer (NSCLC) with mutation BRAF V600E.
- The treatment of patients with locally advanced or metastatic anaplastic thyroid cancer (ATC) with mutation BRAF V600E and with no satisfactory locoregional therapy options.
- The treatment of adult and pediatric patients aged 6 years and older with unresectable or metastatic solid tumors with mutation BRAF V600E who have progressed after prior treatment and have no satisfactory alternative therapy options. (This indication of Trametinib is approved under accelerated approval on behalf of the overall response rate and duration of response).
- The treatment of pediatric patients aged 1 year and older with low-grade glioma (LGG) with a mutation BRAF V600E who require systemic therapy.
Dosage and Side Effects of Trametinib Tablets
The recommended dosage of Trametinib tablets in adults is 2 mg orally once daily. The recommended dosage in pediatric patients is based on body weight. Patients weighing 26 kg to 37 kg should take 1 mg orally once daily, patients weighing 38 kg to 50 kg should take 1.5 mg orally once daily, and patients weighing 51 kg or greater should take 2 mg orally once daily. Take Trametinib at least 1 hour prior to or at least 2 hours after a meal without crushing or breaking the tablets.
The most common side effects of Trametinib tablet as a single agent include diarrhea, rash, and lymphedema. Side effects of Trametinib in combination with dabrafenib include:
- Unresectable or metastatic melanoma: hypertension, pyrexia, nausea, chills, diarrhea, vomiting, rash, and peripheral edema.
- Adjuvant treatment of melanoma: headache, pyrexia, nausea, fatigue, chills, diarrhea, vomiting, rash, arthralgia, and myalgia.
- NSCLC: vomiting, pyrexia, fatigue, nausea, hemorrhage, diarrhea, dry skin, decreased appetite, edema, chills, rash, cough, and dyspnea.
- Adult patients with solid tumors: headache, pyrexia, fatigue, nausea, rash, chills, hemorrhage, cough, vomiting, constipation, diarrhea, myalgia, arthralgia, and edema.
- Pediatric patients with solid tumors: vomiting, pyrexia, fatigue, cough, diarrhea, headache, dry skin, abdominal pain, dermatitis acneiform, nausea, hemorrhage, constipation, paronychia, and rash.
- Pediatric patients with LGG: vomiting, pyrexia, rash, headache, musculoskeletal pain, diarrhea, fatigue, dry skin, nausea, abdominal pain, hemorrhage, and dermatitis acneiform.
